| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/23/2006 | WO2006031786A2 Protein a compositions and methods of use |
| 03/23/2006 | WO2006031727A2 Peptides for treatment of autoimmune diseases |
| 03/23/2006 | WO2006031554A2 Methods for preventing, removing, reducing, or disrupting biofilm |
| 03/23/2006 | WO2006031376A2 Use of antioxidants for treating degenerative disc disease |
| 03/23/2006 | WO2006031375A2 Use of intradiscally administered autologous cells producing type i interferon for the treatment of degenerative disc disease |
| 03/23/2006 | WO2006031363A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 03/23/2006 | WO2006031353A2 Vascular endothelial growth factor fusion constructs and uses thereof |
| 03/23/2006 | WO2006031330A2 METHOD OF REDUCING THE EFFECTS OF Aβ AND COMPOSITIONS THEREFORE |
| 03/23/2006 | WO2006031267A2 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 03/23/2006 | WO2006031226A1 Region of factor ixa protease domain that interacts with factor viiia and methods therefor |
| 03/23/2006 | WO2006031142A1 Biologically active material, method for the production thereof and a therapeutic agent based thereon |
| 03/23/2006 | WO2006031117A1 Lipoxygenase inhibitor peptides and their use |
| 03/23/2006 | WO2006030887A1 External preparation for treating skin ulcer |
| 03/23/2006 | WO2006030803A1 Purinenucleoside derivative modified in 8-position and medicinal use thereof |
| 03/23/2006 | WO2006030730A1 Permucosal composition and method of improving permucosal absorption |
| 03/23/2006 | WO2006030693A1 Agents for overcoming hair troubles and method of screening the same |
| 03/23/2006 | WO2006030118A1 Use of gilz protein expressed in dendritic cells to modulate an antigen-specific immune response |
| 03/23/2006 | WO2006029981A1 Abin-mediated protection against lung inflammatory disease |
| 03/23/2006 | WO2006029852A1 Polypeptide species useful for the treatment of neurological disorders |
| 03/23/2006 | WO2006029728A1 ICA512 COUPLES INSULIN SECRETION AND GENE EXPRESSION IN β-CELLS |
| 03/23/2006 | WO2006029634A2 Pharmaceutical compositions containing insulin and insulinotropic peptide |
| 03/23/2006 | WO2006029578A1 Interleukin-15 antagonist peptide |
| 03/23/2006 | WO2006029507A1 Inhibition of feline calicivirus replication by asparaginase |
| 03/23/2006 | WO2006029492A1 Kunitz-type recombinant inhibitor. |
| 03/23/2006 | WO2006029487A2 Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis |
| 03/23/2006 | WO2006000844A3 Hydrocephalus treatment |
| 03/23/2006 | WO2005120474A3 Phophodiesterase 10a inhibitors to amplify the action of glp1-mimetics or dpp-iv inhibitors in diabetes |
| 03/23/2006 | WO2005113720A3 A strategy for designing patient-specific anti-cancer drugs |
| 03/23/2006 | WO2005112542A3 Cartilage and bone repair composition |
| 03/23/2006 | WO2005112541A3 Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells |
| 03/23/2006 | WO2005099774A3 Diagnosis and treatment of myeloid and lymphoid cell cancers |
| 03/23/2006 | WO2005089462A3 Methods and systems for treatment of neurological diseases of the central nervous system |
| 03/23/2006 | WO2005086915A3 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| 03/23/2006 | WO2005079284A3 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 03/23/2006 | WO2005078094A3 Stabilized rnas as transfection controls and silencing reagents |
| 03/23/2006 | WO2005077337A3 Dispersions prepared by use of self-stabilizing agents |
| 03/23/2006 | WO2005065017A3 Methods of inducing il-10 production |
| 03/23/2006 | WO2005059133A3 Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent |
| 03/23/2006 | WO2005058366A3 Compositions comprising two different populations of polymer-active agent conjugates |
| 03/23/2006 | WO2005048985A3 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 03/23/2006 | WO2005048949A3 Rescue agents for treating botulinum toxin intoxications |
| 03/23/2006 | WO2005048913A3 Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment |
| 03/23/2006 | WO2005047459A3 Sars nucleic acids, proteins, antibodies, and uses thereof |
| 03/23/2006 | WO2005042006A3 Use of ephrins and related molecules to regulate cellular proliferation |
| 03/23/2006 | WO2005019251A3 Novel fungal proteins and nucleic acids encoding same |
| 03/23/2006 | WO2005000201A3 Modulation of apolipoprotein (a) expression |
| 03/23/2006 | WO2004111087A3 Chemokin-binding protein thap1, methods and use thereof |
| 03/23/2006 | WO2004105504A3 Dietary supplements and methods of preparing and administering dietary supplements |
| 03/23/2006 | WO2004098502A3 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses. |
| 03/23/2006 | WO2004096254A3 Transferrin conjugates for tumor treatment |
| 03/23/2006 | WO2004096117A3 Drug delivery systems comprising transferrin-nucleic acid conjugates |
| 03/23/2006 | WO2004094648A3 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 03/23/2006 | WO2004087057A3 Methods for inhibition of angiogenesis |
| 03/23/2006 | WO2004065546A3 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1 |
| 03/23/2006 | WO2004019876A3 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/23/2006 | WO2003083085A3 Transporters and ion channels |
| 03/23/2006 | US20060064778 Using vector transformation to insert plasmid which express antisense sequences which reduce proanthocyanidin (PA) in plant seed coats; enhancing feed quality and digestibility |
| 03/23/2006 | US20060063941 Perindopril |
| 03/23/2006 | US20060063923 4-1BB peptides and methods for use |
| 03/23/2006 | US20060063922 Epidermal differentiation factor |
| 03/23/2006 | US20060063807 Low molecular weight peptidomimetic growth hormone secretagogues |
| 03/23/2006 | US20060063748 Methods for treating psychosis associated with interferson-alpha therapy |
| 03/23/2006 | US20060063729 Ocular gene therapy |
| 03/23/2006 | US20060063728 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 03/23/2006 | US20060063727 Tr4/tr2 response elements |
| 03/23/2006 | US20060063722 Compound similar to dapaglifozin, but with ethyl group replacing the ethoxy group |
| 03/23/2006 | US20060063721 AI-2 compounds and analogs based on salmonella typhimurium LsrB structure |
| 03/23/2006 | US20060063719 Methods for treating diabetes |
| 03/23/2006 | US20060063718 Topical glutathione compositions |
| 03/23/2006 | US20060063717 Novel inhibitor of beta amyloid cleavage |
| 03/23/2006 | US20060063716 Intermedin and its uses |
| 03/23/2006 | US20060063715 Multivalent antigen-binding proteins |
| 03/23/2006 | US20060063714 Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides |
| 03/23/2006 | US20060063713 Methods for restoring immune balance for the treatment of T-cell mediated diseases |
| 03/23/2006 | US20060063712 Pharmaceutical composition for inhibiting influenza virus infection and reproduction |
| 03/23/2006 | US20060063711 Use of sglt homolog |
| 03/23/2006 | US20060063710 Flj20647s as modifiers of the p21 pathway and methods of use |
| 03/23/2006 | US20060063709 Nuclear factors associated with transcriptional regulation |
| 03/23/2006 | US20060063708 Administering melanocyte stimulating hormone to peripheral tissue |
| 03/23/2006 | US20060063707 Compositions for enhancing memory and methods therefor |
| 03/23/2006 | US20060063706 Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals; treating infection caused by methicillin-resistant Staphylococcus aureus |
| 03/23/2006 | US20060063705 Use of alpha-MSH and EPO for preventing or treating ischemic conditions |
| 03/23/2006 | US20060063704 Somatostatin-dopamine chimeric analogs |
| 03/23/2006 | US20060063703 Methods for treating cancer-related fatigue |
| 03/23/2006 | US20060063702 Neuromedin U 2 receptor agonists and uses thereof |
| 03/23/2006 | US20060063701 synthetic polypeptides capable of binding complement component C5a anaphylatoxin and inhibiting complement component C5a activity; antiinflammatory agents |
| 03/23/2006 | US20060063700 Methods to stimulate insulin production by pancreatic Beta-cells |
| 03/23/2006 | US20060063699 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 03/23/2006 | US20060063698 for nasal administration across the mucous membrane, comprising a free-flowing powder of ion exchange resin divinylbenzene crosslinked polystyrenesulfonic acid or salts thereof ionically bound to the therapeutic peptide such as nesiritide or insulin |
| 03/23/2006 | US20060063258 Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders |
| 03/23/2006 | US20060063256 Human regulatory T cells and uses thereof |
| 03/23/2006 | US20060063249 Human cathepsin |
| 03/23/2006 | US20060063248 Butyrylcholinesterase variants and methods of use |
| 03/23/2006 | US20060063244 Comprises ribonuclease barnase marker gene; libraries; drug resistance |
| 03/23/2006 | US20060063235 DNA encoding the human serine protease C-E |
| 03/23/2006 | US20060063230 Sulfatases and methods of use thereof |
| 03/23/2006 | US20060063203 Vascular endothelial cell growth factor variants and uses thereof |
| 03/23/2006 | US20060063200 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/23/2006 | US20060063176 Methionyl tRNA synthetase polynucleotides |
| 03/23/2006 | US20060063149 Compositions and methods for detecting pathogen infection |